Tenderwize
Zurück zur Suche

Open-house rebate agreement for Naproxen/Esomeprazole

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Aug 31, 2027 · 370 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen/Esomeprazol (ATC-Code nach WHO: M01AE52)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

The structured data marks electronic submission as not allowed and submission method as not allowed, while the XML noti...

Key participation conditions are contained in documents not provided in the extracted text, including 'Anschreiben', 'E...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive rebate agreement for pharmaceutical products containing Naproxen/Esomeprazole (ATC M01AE52).
  • Open-House model: contract conclusion is open to all interested pharmaceutical companies that meet and accept the participation conditions.
Vollständige Zusammenfassung anzeigen

This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements for Naproxen/Esomeprazole (ATC M01AE52) with AOK PLUS. The notice states that any interested pharmaceutical company meeting the participation conditions may join during the participation period, with no individual negotiations and no exclusivity. The contract term ends no later than 31.08.2027. Participation documents are available via DTVP, but the extracted procurement documents were not provided, so document-specific requirements could not be fully analyzed.

Risiken

The structured data marks electronic submission as not allowed and submission method as not allowed, while the XML noti...

Key participation conditions are contained in documents not provided in the extracted text, including 'Anschreiben', 'E...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • Submission of the completed declaration of non-existence of exclusion grounds under §§ 123, 124 GWB is required.

Administrative

  • The company must meet and accept the participation conditions in the documents.

Auftraggeber

Ort

Erfurt, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Naproxen/Esomeprazole

Single lot for a non-exclusive rebate agreement concerning the pharmaceutical product Naproxen/Esomeprazole (ATC M01AE52). Scope is supply of pharmaceutical products under an Open-House model. Place of performance is Dresden, Germany. The lot is a framework agreement/open-house style arrangement with no guaranteed minimum purchase volume and no exclusivity. Lot information comes from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Aug 2025 - Aug 2027

Kategorie

Pharmaceutical products

Frist

Deadline Aug 31, 2027

Vergabedetails

Veröffentlichungsdatum
08 Jul 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
446354-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3